was read the article
array:23 [ "pii" => "S2530016422001136" "issn" => "25300164" "doi" => "10.1016/j.endinu.2022.01.011" "estado" => "S300" "fechaPublicacion" => "2022-12-01" "aid" => "1300" "copyright" => "SEEN y SED" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Endocrinol Diabetes Nutr. 2022;69:771-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S2530016422000295" "issn" => "25300164" "doi" => "10.1016/j.endinu.2021.10.016" "estado" => "S300" "fechaPublicacion" => "2022-12-01" "aid" => "1265" "copyright" => "SEEN y SED" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Endocrinol Diabetes Nutr. 2022;69:779-90" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Seasonality of month of birth in patients with autoimmune endocrine diseases: A systematic review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "779" "paginaFinal" => "790" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Estacionalidad en el mes de nacimiento en pacientes con enfermedades endocrinas autoinmunes: revisión sistemática" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2680 "Ancho" => 2341 "Tamanyo" => 415702 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Flow chart depicting the main details on the screening process, with selection and exclusion reasons for the articles finally included in this systematic review, adapted following the indications in <span class="elsevierStyleInterRef" id="intr0005" href="http://www.prisma-statement.org/">http://www.prisma-statement.org</span> [Page 2021].</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana M. Ramos-Leví, Gloria Collado, Monica Marazuela" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Ana M." "apellidos" => "Ramos-Leví" ] 1 => array:2 [ "nombre" => "Gloria" "apellidos" => "Collado" ] 2 => array:2 [ "nombre" => "Monica" "apellidos" => "Marazuela" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2530018022001810" "doi" => "10.1016/j.endien.2022.11.017" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001810?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422000295?idApp=UINPBA00004N" "url" => "/25300164/0000006900000010/v1_202211180721/S2530016422000295/v1_202211180721/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2530016422002403" "issn" => "25300164" "doi" => "10.1016/j.endinu.2022.11.001" "estado" => "S300" "fechaPublicacion" => "2022-12-01" "aid" => "1361" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Endocrinol Diabetes Nutr. 2022;69:769-70" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Endocrinología, Diabetes y Nutrición: resumen del año 2022" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "769" "paginaFinal" => "770" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Endocrinología, Diabetes y Nutrición: Year in Review 2022" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Assumpta Caixàs, María Ballesteros, José Antonio Gimeno, Pedro Iglesias, Edelmiro Menéndez, Nuria Valdés, Ana M Wägner" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Assumpta" "apellidos" => "Caixàs" ] 1 => array:2 [ "nombre" => "María" "apellidos" => "Ballesteros" ] 2 => array:2 [ "nombre" => "José Antonio" "apellidos" => "Gimeno" ] 3 => array:2 [ "nombre" => "Pedro" "apellidos" => "Iglesias" ] 4 => array:2 [ "nombre" => "Edelmiro" "apellidos" => "Menéndez" ] 5 => array:2 [ "nombre" => "Nuria" "apellidos" => "Valdés" ] 6 => array:2 [ "nombre" => "Ana M" "apellidos" => "Wägner" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2530018022001901" "doi" => "10.1016/j.endien.2022.11.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001901?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422002403?idApp=UINPBA00004N" "url" => "/25300164/0000006900000010/v1_202211180721/S2530016422002403/v1_202211180721/es/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Causes of hyperprolactinaemia in the primary care setting: How to optimise hyperprolactinaemia management" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "771" "paginaFinal" => "778" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Ana M. García Cano, Lucía Jiménez Mendiguchía, Marta Rosillo Coronado, Ana Gómez Lozano, Ángel Luis del Rey-Mejías, María Fresco Merino, Marta Marchán Pinedo, Marta Araujo-Castro" "autores" => array:8 [ 0 => array:4 [ "nombre" => "Ana M." "apellidos" => "García Cano" "email" => array:1 [ 0 => "anamaria.garciac@salud.madrid.org" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Lucía" "apellidos" => "Jiménez Mendiguchía" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Marta" "apellidos" => "Rosillo Coronado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Ana" "apellidos" => "Gómez Lozano" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 4 => array:3 [ "nombre" => "Ángel Luis" "apellidos" => "del Rey-Mejías" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 5 => array:3 [ "nombre" => "María" "apellidos" => "Fresco Merino" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "Marta" "apellidos" => "Marchán Pinedo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 7 => array:4 [ "nombre" => "Marta" "apellidos" => "Araujo-Castro" "email" => array:1 [ 0 => "marta.araujo@salud.madrid.org" ] "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:5 [ 0 => array:3 [ "entidad" => "Department of Clinical Biochemistry, Hospital Universitario Ramón y Cajal Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Endocrinology & Nutrition, Hospital Universitario Ramón y Cajal Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Unit of Data Science, Ramón y Cajal University Hospital, IRYCIS, Madrid 28034, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Department of Health Science, Universidad Alcalá, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding authors." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Causas de hiperprolactinemia en Atención Primaria. Cómo optimizar su manejo" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 934 "Ancho" => 1675 "Tamanyo" => 110946 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Study's inclusion process of hyperprolactinaemia.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Prolactin is a protein synthesised and released principally by lactotrophs in the anterior pituitary gland. Dopamine is established as the principal inhibitor of prolactin synthesis and secretion.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">1</span></a> Factors principally inducing prolactin synthesis and secretion are oestrogen, dopamine receptor antagonists, thyrotropin-releasing hormone and epidermal growth factor.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Hyperprolactinaemia is characterised by increased production of prolactin, and different factors can lead to prolactin elevation, including pharmacological, physiological, and pathological causes. Therefore, a comprehensive study is necessary to ensure an adequate aetiological diagnosis in order to adapt the appropriate treatment and follow-up. Regarding its prevalence, different studies have reported variable figures depending on the population studied, ranging from 0.4% in asymptomatic patients to 9–17% in women with amenorrhoea and/or polycystic ovary syndrome.<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">3–5</span></a> Furthermore, some authors estimate that the prevalence of hyperprolactinaemia has been increasing in recent years, probably as a consequence of the increase of the consumption of hyperprolactinaemic drugs,<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">4</span></a> and due to the fact that serum prolactin is a parameter that is increasingly requested. Moreover, differences by sex have been reported, describing prevalence up to five times higher in women than in men.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Differential diagnosis can be complex. There are causes which must be considered: physiological causes, such as pregnancy and lactation, pathological causes including hypothalamic and/or pituitary diseases, and pharmacological causes.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">2,6</span></a> The laboratory plays an important role in guiding the diagnosis of hyperprolactinaemia. It all starts with the measurement of isolated serum prolactin levels, always in the context of a non-traumatic venipuncture.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">2</span></a> In cases of discrete elevations of prolactin and/or prolactin levels discordant with the clinical picture, the measurement of this parameter should be repeated in two samples taken at 15–20-min intervals without repeated venipuncture (cannulated prolactin test). A common cause of hyperprolactinaemia is macroprolactinaemia.<a class="elsevierStyleCrossRefs" href="#bib0170"><span class="elsevierStyleSup">7,8</span></a> The most common cause of non-tumoural hyperprolactinaemia has been found to be pharmacological. Prolactin level varies according to pharmacological group,<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">2,9–11</span></a> ranging from 25 to 100<span class="elsevierStyleHsp" style=""></span>ng/ml, but metoclopramide, risperidone and phenothiazines can lead to 200<span class="elsevierStyleHsp" style=""></span>ng/ml.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">2</span></a> Some authors reported that antipsychotic drug-induced hyperprolactinaemia has been estimated to occur in up to 70% of patients with schizophrenia.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">9</span></a> On the other hand, prolactinomas are the most frequent organic cause of prolactin excess and the most common type of hormone-secreting pituitary tumours.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">12</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">The aim of our study is to determine the causes of hyperprolactinaemia in the primary care setting and analyse whether there are clinical or hormonal differences depending on the cause of the hyperprolactinaemia. The final objective is to detect improvements in the care process, which could optimise visits to the specialist as well as the treatment itself, from the first determination made in these patients.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Material and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Sample selection</span><p id="par0025" class="elsevierStylePara elsevierViewall">The Clinical Biochemistry Laboratory of Hospital Ramón y Cajal receives samples from 20 primary care centres, which represent an estimated population of 550,000 inhabitants. All serum prolactin samples from these were selected during the period 2019–2020 (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1630 patients). The clinical history was reviewed in order to collect clinical and analytical data.</p><p id="par0030" class="elsevierStylePara elsevierViewall">Only cases of hyperprolactinaemia, based on our laboratory ranges (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>501 patients), were selected. There were 90 patients who were excluded from the analysis of the causes of hyperprolactinaemia, 85 females and 5 males, because the final cause of hyperprolactinaemia was not available, as many of them had not yet completed the study or had not yet come for consultation (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Definitions</span><p id="par0035" class="elsevierStylePara elsevierViewall">Hyperprolactinaemia is defined as serum prolactin above 19.4<span class="elsevierStyleHsp" style=""></span>ng/ml in men and above 26.5<span class="elsevierStyleHsp" style=""></span>ng/ml in women, based on our laboratory range. Hyperprolactinaemia is classified into different groups according to aetiology: (i) physiological (pregnancy, lactation, venipuncture stress, macroprolactinaemia), (ii) pathological (organic by hypothalamic and/or pituitary diseases, chronic renal failure, and primary hypothyroidism), (iii) pharmacological and (iv) idiopathic.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Regarding the physiological causes, pregnancy or lactation were confirmed with data from the medical history. Venipuncture stress included patients who normalised serum prolactin levels at a subsequent extraction in the context of no prior intervention to that second withdrawal. The causes of their first elevation could be attributed to physiological situations such as exercise, anxiety, food intake, stress and venipuncture. Macroprolactinaemia was defined when the ratio Total serum prolactin-Free prolactin/Total prolactin ×100 exceeds 60% (recovery of 40%).<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">13</span></a> In addition, the cause was defined as organic if it was of tumoural origin (prolactin-producing pituitary adenomas, non-functioning pituitary macroadenomas or other lesions with displacement of the pituitary stalk) and due to systemic diseases, such as overt primary hypothyroidism (with TSH levels above normal range and low FT4) and renal disease with a glomerular filtration rate<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60<span class="elsevierStyleHsp" style=""></span>ml/min/1.73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>. It was classified as pharmacological in those patients who were treated with drugs considered likely to cause an increase in prolactin levels, with normalisation of the serum prolactin after withdrawal or no evidence of another cause if withdrawal was not possible. The drugs considered to cause hyperprolactinaemia were anticonvulsants, antidepressants, antihistamines H2, dopamine receptor blockers and dopamine synthesis inhibitor, oestrogens (oral contraceptives), neuroleptics/antipsychotics<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">2</span></a> and antihypertensives (verapamil and methyldopa).<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">1</span></a> Idiopathic hyperprolactinaemia included patients who did not correspond to any of the previous groups but who maintained elevated prolactin levels.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Laboratory methods</span><p id="par0045" class="elsevierStylePara elsevierViewall">Total and post-polyethylene glycol (PEG) serum prolactin levels were determined by immunoassay (Abbott Architect, Chicago, IL, USA) calibrated against the WHO Third International Standard for prolactin (84/500). Total coefficient variation is 4.7% and 3.6% at mean prolactin concentrations of 7 and 35.8<span class="elsevierStyleHsp" style=""></span>ng/ml, respectively; sensitivity is 0.6<span class="elsevierStyleHsp" style=""></span>ng/ml.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">14</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">In order to determine the presence of macroprolactinaemia in the sample, it was precipitated with 25% PEG. Next, it was added to the same sample volume, vortexed and centrifuged and then, the prolactin in the supernatant was measured a second time. Free serum prolactin is defined as the concentration of prolactin in the supernatant after precipitation with PEG. PEG-precipitable prolactin (%) represents the amount of macroprolactin, which is calculated according to the formula: (Total serum prolactin-Free serum prolactin)/Total serum prolactin ×100.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">15</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Data collection and statistical analysis</span><p id="par0055" class="elsevierStylePara elsevierViewall">Study data were collected and managed using REDCap electronic data capture tools hosted at Hospital Ramón y Cajal Madrid.<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">16,17</span></a> REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for data integration and interoperability with external sources.</p><p id="par0060" class="elsevierStylePara elsevierViewall">All statistical analyses were performed with STATA.15. The Shapiro–Wilk test was used to check the normality assumption and Levene's test was used to evaluate variance homogeneity. Categorical variables are expressed as percentages and absolute values. Quantitative variables are expressed as mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>standard deviation or median. For variables following normal distribution, we used Student's <span class="elsevierStyleItalic">t</span> test to compare the differences between the two groups. The chi-square test was used to compare the categorical variables between independent groups. In all cases, the statistical significance threshold was set as <0.05 and two-tailed analyses were performed.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Results</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Prevalence of hyperprolactinaemia</span><p id="par0065" class="elsevierStylePara elsevierViewall">The prevalence of hyperprolactinaemia in our cohort population was 30.7% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>501), of which 89.6% of the patients were female. The mean age of the patients was 34.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>10.8 years (34.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>10.5 years old in females and 37.8<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>14.5 years old in males, <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.303). The clinical manifestations reported by patients undergoing prolactin testing in primary care are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. The most frequent reason for prolactin testing in women was irregular menstruation and amenorrhoea; and gynaecomastia in men.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Referral to the medical specialist</span><p id="par0070" class="elsevierStylePara elsevierViewall">Of the 501 patients with hyperprolactinaemia, 194 were referred to the Endocrinology Department and 164 to the Gynaecology Department (62 of these patients had also been assessed by the endocrinologist). The most frequent cause of hyperprolactinaemia in patients referred to the Endocrinology Department was inadequate sample collection, while the most frequent cause in patients referred to the Gynaecology Department (without assessment by Endocrinology) was idiopathic hyperprolactinaemia (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). Overall, the most frequent cause of referral was idiopathic (27.0%) and pharmacological (24.0%).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Causes of hyperprolactinaemia</span><p id="par0075" class="elsevierStylePara elsevierViewall">The aetiological study was completed in 411 patients. The most frequent cause was pharmacological in 39.1% (36.3% females and 61.7% males). In 8.5% of the cases the cause was tumour. In females (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>364), the most frequent cause was pharmacological, and the most frequent tumour was microprolactinoma (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>22), followed by non-functioning pituitary macroadenoma (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>7), and only one case of macroprolactinoma was detected. The other causes were infrequent (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). In the male group (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>47), the main tumoural cause was non-functioning pituitary macroadenoma (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>4), with only one case of microprolactinoma and another case of macroprolactinoma. Patients with tumoural hyperprolactinaemia presented higher serum prolactin levels than patients in the other groups, as well as more frequently having galactorrhoea and headache (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Discussion</span><p id="par0080" class="elsevierStylePara elsevierViewall">The main finding of this study is that 30% of the patients tested for serum prolactin levels due to compatible symptoms of hyperprolactinaemia had hyperprolactinaemia, the most frequent cause being pharmacological. Furthermore, it was found that patients with tumoural hyperprolactinaemia had higher prolactin levels, and symptoms such as galactorrhoea and headache were more frequent than in patients with hyperprolactinaemia of other origins.</p><p id="par0085" class="elsevierStylePara elsevierViewall">The prevalence of hyperprolactinaemia in the cohort population, which includes patients with symptoms compatible with high prolactin levels, with a high pretest probability of hyperprolactinaemia, has been found to be 30%. Other studies have described lower figures, ranging from less than 1% in a healthy population to between 5% and 14% in women with secondary amenorrhoea.<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">18</span></a> These data are difficult to compare with other studies, given that the clinical context in which this alteration has been studied is very different.<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">3,4,6</span></a> Most authors agree that the prevalence is higher in patients who present symptoms of hyperprolactinaemia, such as amenorrhoea, galactorrhoea, or infertility.<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">1,19</span></a> In this study, this prevalence has been calculated in a population in which this parameter is measured by clinical manifestations compatible with hyperprolactinaemia in a primary care setting. This fact may justify the differences between the reported prevalence data compared to other studies. In fact, as far as it is known, there is only one previous study that has also evaluated the prevalence of hyperprolactinaemia in a primary care setting in patients with a high pretest probability.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">6</span></a> In this previous study the prevalence of hyperprolactinaemia in patients tested for serum prolactin due to compatible symptoms was 42.3%, which is similar to that reported in our study.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Another important point in our series is that almost 60% of patients with hyperprolactinaemia were referred to the Endocrinology and/or Gynaecology Departments for evaluation. However, less than 10% of these cases actually presented with tumour as the cause. In order to optimise referrals to the Endocrinology and Gynaecology Departments, benign causes of hyperprolactinaemia, such as pregnancy, lactation, or incorrect sample collection, should be always excluded before considering requesting a medical specialist evaluation. Thus, it is highly important to review the medical history (i.e., review of pharmacological treatments likely to raise prolactin), perform a complete physical examination, evaluate clinical findings as well as certain laboratory parameters (i.e., prolactin levels, beta HCG, serum TSH levels, free t4 and serum creatinine).</p><p id="par0095" class="elsevierStylePara elsevierViewall">In cases where a physiological cause has been ruled out, the possibility of macroprolactin should be considered, especially in cases in which the patient is asymptomatic and has normal gonadotropins and sex steroids.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">2,20</span></a> The prevalence of macroprolactinaemia in this study is 4.4%, which does not coincide with that reported by other authors,<a class="elsevierStyleCrossRefs" href="#bib0170"><span class="elsevierStyleSup">7,15,21</span></a> probably because in this study PEG-precipitation has not been performed in all cases in which it should have been done. This finding supports the inclusion of PEG precipitation in the diagnostic algorithm of patients with hyperprolactinaemia to preclude unnecessary further investigations and treatment, especially in asymptomatic patients. Nevertheless, this determination is not available in most primary care centres. It is considered that if physicians in a primary care setting are properly instructed on the indications for testing macroprolactin, it could be a cost-effective measure and lead to avoiding unnecessary referrals to the specialty setting. An algorithm for a referral to a medical specialist is proposed based mainly on the clinical history (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">The most frequent cause of hyperprolactinaemia in the cohort population is pharmacological (39.1%), which coincides with data reported in previous studies.<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">4,11,22</span></a> Along this line, in the PROLEARS study, a population-based retrospective study of 1301 patients with hyperprolactinaemia, 45.9% were drug-induced.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">4</span></a> Nevertheless, the study by Malik et al. reported tumour as the most frequent cause in the primary care setting (37% in women and 27.6% in men).<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">6</span></a> Therefore, in cases of pharmacological hyperprolactinaemia, the role of the physician is to exclude a co-existing hypothalamic-pituitary structural lesion. Also, some authors recommend that psychiatric management be adjusted and drugs substituted for others with a lesser effect on prolactin secretion.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">22</span></a>. If the patient is taking a drug known, which causes hyperprolactinaemia, it is important to determine prolactin levels by withdrawing the drug for at least 72<span class="elsevierStyleHsp" style=""></span>h, provided it is safe.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">23</span></a> This can be controversial especially in patients with severe psychiatric illness who are stable with their treatments, so in these cases it is advisable to do a Pituitary Magnetic Resonance Imaging (MRI).</p><p id="par0105" class="elsevierStylePara elsevierViewall">Furthermore, in 13.4% of patients with hyperprolactinaemia, the cause is inadequate extraction due to stress or exercise and a second extraction or a two-stage extraction would be required to confirm this fact.</p><p id="par0110" class="elsevierStylePara elsevierViewall">One of the most important findings in the current series is that in hyperprolactinaemia of tumoural origin it has been found that serum prolactin levels are higher than in other causes, both in basal prolactin and prolactin at 30<span class="elsevierStyleHsp" style=""></span>min in those cases with serial prolactin sampling. Most authors agree that prolactin levels above 100–150<span class="elsevierStyleHsp" style=""></span>ng/ml correspond to prolactinomas, and in cases of macroadenoma this value would be higher than 250<span class="elsevierStyleHsp" style=""></span>ng/ml.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">2,24</span></a> Serum prolactin values between the upper limits of normal and 100<span class="elsevierStyleHsp" style=""></span>ng/ml may be due to psychoactive drugs, oestrogen, or idiopathic causes, but can also be caused by a microprolactinoma. For this reason, although serum prolactin levels help guide diagnosis, they should be interpreted with caution, since there is overlap between serum prolactin levels in the different aetiologies.<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">19,23–25</span></a> Moreover, in the cannulated prolactin test, hyperprolactinaemia of tumoural origin has higher basal prolactin and 30-minute levels than other causes. Therefore, authors suggest that a single prolactin value between 24 and 94<span class="elsevierStyleHsp" style=""></span>ng/ml should be confirmed with a cannulated study.<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">26</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">In addition, the symptoms presented by the patients studied may point to the diagnosis of a tumoural cause, which presents galactorrhoea and headache in a greater proportion than in those causes of non-tumoural origin. There is a study that did not find such differences in symptoms between the tumoural and non-tumoural groups,<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">25</span></a> which may be due to differences in the populations studied, since in this study the group of patients with non-tumoural hyperprolactinaemia has been much larger. Furthermore, in other studies, the different clinical manifestations are not studied according to their cause, while they are distinguished between sex: female patients suffer amenorrhoea and irregular menstruation, and on the other hand, male patients show infertility and erectile dysfunction.<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">6,25,27</span></a> Studies suggest that the prolactin level is commonly associated with different apparent clinical pictures.<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">19</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall">Many of the cases of hyperprolactinaemia finish up being classified as idiopathic (29%); it should be assumed that some patients classified in this group may have a small prolactinoma not visible on imaging tests.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">3</span></a> Prevalence of idiopathic hyperprolactinaemia in previous studies ranged from in 3.6–27.8% of all cases. This wide range is probably reflected in the differences found in the population studied and it may also be related to an underestimation of macroprolactin or an incomplete work-up of patients.<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">4,27</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">The limitations of the study must be taken into consideration. They are mainly related to the retrospective nature of the study, and the possible bias induced by individual decisions in the consideration of referral to medical specialist and to test prolactin levels. Second, macroprolactinaemia may have been underdiagnosed in the study, as macroprolactin is not routinely screened in all patients. However, this study has several strengths and it is remarkable that all serum prolactin tested in a defined period of time has been included. In addition, this is the largest study assessing hyperprolactinaemia in Spain, and all patients were evaluated using the same prolactin assay.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conclusion</span><p id="par0130" class="elsevierStylePara elsevierViewall">Hyperprolactinaemia is common in patients evaluated in the primary care setting, but almost 50% are due to pharmacological treatments or improper sample extraction. It is necessary to establish protocols for referral to specialised medicine to optimise health resources and avoid unnecessary studies.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Protection of persons</span><p id="par0135" class="elsevierStylePara elsevierViewall">All procedures performed on the participants of the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Ethical approval</span><p id="par0140" class="elsevierStylePara elsevierViewall">The study was evaluated and approved by the ethics committee of the Hospital Ramón y Cajal (approval date: 27/04/2021, ACTA 412).</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Data protection</span><p id="par0145" class="elsevierStylePara elsevierViewall">The authors declare that no patient data appear in this article.</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Informed consent</span><p id="par0150" class="elsevierStylePara elsevierViewall">The exemption of informed consent is requested, because it is a retrospective study.</p><p id="par0155" class="elsevierStylePara elsevierViewall">Compliance with Ethical Standards.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Financial support</span><p id="par0160" class="elsevierStylePara elsevierViewall">No financial support has been received.</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Conflict of interest</span><p id="par0165" class="elsevierStylePara elsevierViewall">The authors have no conflict of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:17 [ 0 => array:3 [ "identificador" => "xres1803569" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background and purpose" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusion" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1576475" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1803568" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Antecedentes y objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusión" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1576476" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Material and methods" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Sample selection" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Definitions" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Laboratory methods" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Data collection and statistical analysis" ] ] ] 6 => array:3 [ "identificador" => "sec0035" "titulo" => "Results" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Prevalence of hyperprolactinaemia" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Referral to the medical specialist" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "Causes of hyperprolactinaemia" ] ] ] 7 => array:2 [ "identificador" => "sec0055" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0060" "titulo" => "Conclusion" ] 9 => array:2 [ "identificador" => "sec0065" "titulo" => "Protection of persons" ] 10 => array:2 [ "identificador" => "sec0070" "titulo" => "Ethical approval" ] 11 => array:2 [ "identificador" => "sec0075" "titulo" => "Data protection" ] 12 => array:2 [ "identificador" => "sec0080" "titulo" => "Informed consent" ] 13 => array:2 [ "identificador" => "sec0085" "titulo" => "Financial support" ] 14 => array:2 [ "identificador" => "sec0090" "titulo" => "Conflict of interest" ] 15 => array:2 [ "identificador" => "xack636377" "titulo" => "Acknowledgements" ] 16 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2021-12-30" "fechaAceptado" => "2022-01-19" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1576475" "palabras" => array:4 [ 0 => "Hyperprolactinaemia" 1 => "Prolactinoma" 2 => "Prolactin" 3 => "Macroprolactinaemia" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1576476" "palabras" => array:4 [ 0 => "Hiperprolactinemia" 1 => "Prolactinoma" 2 => "Prolactina" 3 => "Macroprolactinemia" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background and purpose</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To analyse the causes of hyperprolactinaemia in patients with symptoms compatible with hyperprolactinaemia evaluated in a primary care setting.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Patients and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A retrospective study of all patients tested for serum prolactin levels between 2019 and 2020 in 20 primary care centres at the Hospital Ramón y Cajal in Madrid. Hyperprolactinaemia is defined as a serum prolactin<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>19.4<span class="elsevierStyleHsp" style=""></span>ng/ml in men and >26.5<span class="elsevierStyleHsp" style=""></span>ng/ml in women. Aetiology is grouped into physiological (pregnancy, lactation, inadequate venipuncture, macroprolactinaemia), pharmacological, pathological (hypothalamic and/or pituitary diseases, chronic renal failure, primary hypothyroidism), and idiopathic.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">In 1630 patients tested for serum prolactin, 30.7% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>501) had hyperprolactinaemia. Of these 501 patients, 89.6% were females. 149 patients were referred to the Endocrinology Department and 164 to the Gynaecology Department. Aetiological diagnosis of hyperprolactinaemia was achieved in 411 out of 501 cases. The most frequent cause of hyperprolactinaemia was pharmacological, in 39.1%. The second more frequent cause was idiopathic (29%) and less common were inadequate venipuncture extraction (13.4%), tumour (8.5%) and macroprolactinaemia (3.9%). Patients with tumoural hyperprolactinaemia presented higher serum prolactin levels (87.0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>80.19 vs 49.7<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39.62<span class="elsevierStyleHsp" style=""></span>ng/ml, <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.010). In addition, symptoms, such as galactorrhoea (33.3% vs 16.5%, <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.018), and headache (25.7% vs 13.3%, <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.045), were more frequent than in patients of the other aetiological groups.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusion</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Hyperprolactinaemia is common among patients evaluated in a primary care setting with symptoms of hyperprolactinaemia, but more than 50% of cases are due to pharmacological treatments or improper sample extraction. It is necessary to establish referral protocols to specialised medicine to optimise healthcare resources and avoid unnecessary studies.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background and purpose" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusion" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Antecedentes y objetivo</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Analizar las causas de la hiperprolactinemia en pacientes con síntomas compatibles de hiperprolactinemia evaluados en el ámbito de Atención Primaria.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Pacientes y métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Estudio retrospectivo de todos los pacientes a los que se les realizó la determinación de prolactina sérica entre 2019 y 2020 en 20 centros de Atención Primaria pertenecientes al área del Hospital Ramón y Cajal de Madrid. La hiperprolactinemia se ha definido como una prolactina sérica<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>19,4<span class="elsevierStyleHsp" style=""></span>ng/ml en hombres y<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>26,5<span class="elsevierStyleHsp" style=""></span>ng/ml en mujeres. La etiología se clasificó en fisiológica (embarazo, lactancia, extracción inadecuada, macroprolactinemia), farmacológica, patológica (enfermedades hipotalámicas y/o hipofisarias, insuficiencia renal crónica, hipotiroidismo primario) e idiopática.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">De los 1.630 pacientes con solicitud de prolactina sérica, el 30,7% (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>501) tenía hiperprolactinemia. De estos 501 pacientes, el 89,6% eran mujeres. 149 pacientes fueron derivados al Servicio de Endocrinología y 164 al Servicio de Ginecología. El diagnóstico etiológico de hiperprolactinemia se logró en 411 de los 501 casos. La causa más frecuente de hiperprolactinemia fue la farmacológica, en un 39,1%. La segunda causa fue idiopática (29%) y menos frecuente la extracción inadecuada (13,4%), tumoral (8,5%) y presencia de macroprolactinemia (3,9%). Los pacientes con hiperprolactinemia tumoral presentaron niveles séricos de prolactina más elevados (87,0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>80,19 vs. 49,7<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39,62<span class="elsevierStyleHsp" style=""></span>ng/ml, p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,010). Además, los síntomas, como galactorrea (33,3 frente a 16,5%, p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,018) y dolor de cabeza (25,7 frente a 13,3%, p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,045), fueron más frecuentes que en los pacientes con hiperprolactinemia por otras causas.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusión</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">La hiperprolactinemia es común entre los pacientes evaluados en Atención Primaria con síntomas de hiperprolactinemia, pero más del 50% de los casos se deben a tratamientos farmacológicos o a una extracción inadecuada de la muestra. Es necesario establecer protocolos de derivación a medicina especializada para optimizar los recursos sanitarios y evitar estudios innecesarios.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Antecedentes y objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusión" ] ] ] ] "multimedia" => array:6 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 934 "Ancho" => 1675 "Tamanyo" => 110946 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Study's inclusion process of hyperprolactinaemia.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1489 "Ancho" => 2925 "Tamanyo" => 220626 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Causes of hyperprolactinaemia by sex.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1602 "Ancho" => 2175 "Tamanyo" => 249421 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Proposal of algorithm for referral to medical specialist in Primary Care setting. **Primary Care doctors should also review drugs that could potentially be related to hyperprolactinaemia, consider withdrawal if possible and repeat determination. If PRL continues to be elevated after withdrawal, patients should be referred to Endocrinology. PRL: serum prolactin; PEG: polyethylene glycol.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">The group of other symptoms includes dysmenorrhoea, acne and metrorrhagia in women; and 1 case of anxiety and 1 case in which the reason for the request was unknown in men.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Women (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>449)</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Men (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>52)</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Clinical manifestations \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Clinical manifestations \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Irregular menstruation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">127 (28.3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gynaecomastia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 (30.8%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Amenorrhoea \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">94 (20.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Headache \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 (17.3%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Galactorrhoea \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">72 (16.0%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Erectile dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (9.6%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Other symptoms \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">58 (12.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Decreased libido \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (5.8%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Headache \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54 (12.0%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sterility \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (3.9%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sterility \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">38 (8.5%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Other symptoms \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (3.9%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Decreased libido \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (0.5%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Clinical manifestations reported by patients with hyperprolactinaemia.</p>" ] ] 4 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Cause of hyperprolactinaemia \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Endocrinology assessment (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>196) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Gynaecology assessment (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>103) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Inadequate venipuncture \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">53 (27.3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (<1%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pharmacological \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">39 (20.1%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32 (31.4%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Idiopathic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">38 (19.6%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42 (41.1%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tumour \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28 (16.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 (0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Macroprolactinaemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 (10.0%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (<1%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pregnancy or lactation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (<1%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (<1%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Incomplete study \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 (7.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 (1.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Other causes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (<1%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (<1%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Cause of hyperprolactinaemia in patients who had been referred to a medical specialist.</p>" ] ] 5 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Tumour (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>35) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Other causes (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>376) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>411) mean (standard deviation) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">37.3<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>12.34 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>10.94 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.202 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Male sex (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>411) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14.3% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.2% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>42) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.580 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Amenorrhoea or oligomenorrhoea (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>364) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26.7% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19.8% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>66) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.368 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Galactorrhoea (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>364) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33.3% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>11) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16.5% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>59) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.018 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Erectile dysfunction (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>52) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.9% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.414 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Decreased libido (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>411) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.3% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.492 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Headache (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>411) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25.7% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13.3% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.045 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Basal prolactin (first determination) ng/ml (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>411) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">87.0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>80.19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">49.7<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39.62 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.010 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Basal prolactin (second determination) ng/ml (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>201) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">56.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>52.31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30.3<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>28.47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.017 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Prolactin at 30<span class="elsevierStyleHsp" style=""></span>min<span class="elsevierStyleHsp" style=""></span>ng/ml (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>102) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55.7<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>41.87 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22.2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>16.33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.019 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Differential characteristics between tumoural hyperprolactinaemia and other causes.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:27 [ 0 => array:3 [ "identificador" => "bib0140" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prolactin biology and laboratory measurement: an update on physiology and current analytical issues" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Saleem" 1 => "H. Martin" 2 => "P. Coates" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Biochem Rev" "fecha" => "2018" "volumen" => "39" "paginaInicial" => "3" "paginaFinal" => "16" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30072818" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0145" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Melmed" 1 => "F.F. Casanueva" 2 => "A.R. Hoffman" 3 => "D.L. Kleinberg" 4 => "V.M. Montori" 5 => "J.A. Schlechte" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jc.2010-1692" "Revista" => array:6 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2011" "volumen" => "96" "paginaInicial" => "273" "paginaFinal" => "288" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21296991" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0150" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Challenges and pitfalls in the diagnosis of hyperprolactinemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L. Vilar" 1 => "M. Fleseriu" 2 => "M.D. Bronstein" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1590/0004-2730000003002" "Revista" => array:6 [ "tituloSerie" => "Arq Bras Endocrinol Metabol" "fecha" => "2014" "volumen" => "58" "paginaInicial" => "9" "paginaFinal" => "22" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24728159" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0155" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "E. Soto-Pedre" 1 => "P.J. Newey" 2 => "J.S. Bevan" 3 => "N. Greig" 4 => "G.P. Leese" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Endocrinol (Oxf)" "fecha" => "2017" "volumen" => "86" "paginaInicial" => "60" "paginaFinal" => "67" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0160" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Hiperprolactinemia Majumdar A, Mangal NS. J Hum Reprod Sci. Available from: <a target="_blank" href="https://www.jhrsonline.org/article.asp?issn=0974-1208;year=2013;volume=6;issue=3;spage=168;epage=175;aulast=Majumdar">https://www.jhrsonline.org/article.asp?issn=0974-1208;year=2013;volume=6;issue=3;spage=168;epage=175;aulast=Majumdar</a> [cited 13.5.21]." ] ] ] 5 => array:3 [ "identificador" => "bib0165" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Aetiologies of hyperprolactinaemia: a retrospective analysis from a tertiary healthcare centre" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.A. Malik" 1 => "F. Aziz" 2 => "S.A. Beshyah" 3 => "K.M. Aldahmani" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.18295/squmj.2019.19.02.008" "Revista" => array:6 [ "tituloSerie" => "Sultan Qaboos Univ Med J" "fecha" => "2019" "volumen" => "19" "paginaInicial" => "e129" "paginaFinal" => "e134" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31538011" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0170" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N.A.A. Che Soh" 1 => "N.M. Yaacob" 2 => "J. Omar" 3 => "A. Mohammed Jelani" 4 => "N. Shafii" 5 => "T.S. Tuan Ismail" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/ijerph17249385" "Revista" => array:5 [ "tituloSerie" => "Int J Environ Res Public Health" "fecha" => "2020" "volumen" => "17" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33333970" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1470204517306794" "estado" => "S300" "issn" => "14702045" ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0175" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Zhenhua W, Haizhi C, Jing L, Xiaocong F, Jianhua L, Jianjun L, et al. Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. Asia-Pac Psychiatry. e12469." ] ] ] 8 => array:3 [ "identificador" => "bib0180" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antipsychotics-induced hyperprolactinemia and screening for macroprolactin" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Ruljancic" 1 => "A. Bakliza" 2 => "S. Vuk Pisk" 3 => "N. Geres" 4 => "K. Matic" 5 => "E. Ivezic" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Biochem Med" "fecha" => "2021" "volumen" => "31" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0185" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A focused review of the metabolic side-effects of clozapine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.W.Y. Yuen" 1 => "D.D. Kim" 2 => "R.M. Procyshyn" 3 => "W.J. Panenka" 4 => "W.G. Honer" 5 => "A.M. Barr" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Front Endocrinol" "fecha" => "2021" "volumen" => "12" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0190" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Montejo ÁL" 1 => "C. Arango" 2 => "M. Bernardo" 3 => "J.L. Carrasco" 4 => "B. Crespo-Facorro" 5 => "J.J. Cruz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rpsm.2015.11.003" "Revista" => array:6 [ "tituloSerie" => "Rev Psiquiatr Salud Ment" "fecha" => "2016" "volumen" => "9" "paginaInicial" => "158" "paginaFinal" => "173" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26927534" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0195" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The prolactinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Colao" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Best Pract Res Clin Endocrinol Metab" "fecha" => "2009" "volumen" => "23" "paginaInicial" => "575" "paginaFinal" => "596" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0200" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "American Association of Clinical Endocrinologists, American College of Endocrinology Disease State Clinical Review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Samson SusanbL" 1 => "A.H. Hamrahian" 2 => "S. Ezzat" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4158/EP15938.DSC" "Revista" => array:6 [ "tituloSerie" => "Endocr Pract" "fecha" => "2015" "volumen" => "21" "paginaInicial" => "1427" "paginaFinal" => "1435" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26642103" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0205" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Technical Library | Abbott Core Laboratory [Internet]. Available from: <a target="_blank" href="https://www.corelaboratory.abbott/tl/ous/technical-library.html">https://www.corelaboratory.abbott/tl/ous/technical-library.html</a> [cited 1.6.21]." ] ] ] 14 => array:3 [ "identificador" => "bib0210" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Importance of macroprolactinemia in hyperprolactinemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Kasum" 1 => "D. Pavičić-Baldani" 2 => "P. Stanić" 3 => "S. Orešković" 4 => "J-M. Šarić" 5 => "J. Blajić" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejogrb.2014.10.013" "Revista" => array:6 [ "tituloSerie" => "Eur J Obstet Gynecol Reprod Biol" "fecha" => "2014" "volumen" => "183" "paginaInicial" => "28" "paginaFinal" => "32" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25461348" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0215" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Research Electronic Data Capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P.A. Harris" 1 => "R. Taylor" 2 => "R. Thielke" 3 => "J. Payne" 4 => "N. Gonzalez" 5 => "J.G. Conde" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jbi.2008.08.010" "Revista" => array:6 [ "tituloSerie" => "J Biomed Inform" "fecha" => "2009" "volumen" => "42" "paginaInicial" => "377" "paginaFinal" => "381" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18929686" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0220" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "El Consorcio REDCap: Construyendo una Comunidad Internacional de Socios de Plataformas de Software [Internet]. Available from: <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254481/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254481/</a> [cited 14.7.21]." ] ] ] 17 => array:3 [ "identificador" => "bib0225" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The utility of prolactin serial sampling and the best prolactin cut-offs associated with persistent hyperprolactinemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Cidade-Rodrigues" 1 => "F.M. Cunha" 2 => "C. Chaves" 3 => "M. Silva-Vieira" 4 => "A. Silva" 5 => "S. Garrido" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Porto Biomed J" "fecha" => "2021" "volumen" => "6" "itemHostRev" => array:3 [ "pii" => "S1470204521005787" "estado" => "S300" "issn" => "14702045" ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0230" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and management of hyperprolactinemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "O. Serri" 1 => "C.L. Chik" 2 => "E. Ur" 3 => "S. Ezzat" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Can Med Assoc J" "fecha" => "2003" "volumen" => "169" "paginaInicial" => "575" "paginaFinal" => "581" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0235" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Melgar V, Espinosa E, Sosa E, Rangel MJ, Cuenca D, Ramírez C, et al. Diagnóstico y tratamiento actual de la hiperprolactinemia. Rev Med Inst Mex Seguro Soc. 12." ] ] ] 20 => array:3 [ "identificador" => "bib0240" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Macroprolactinemia in patients with hyperprolactinemia: an experience from a single tertiary center" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P. Chutpiboonwat" 1 => "K. Yenpinyosuk" 2 => "V. Sridama" 3 => "S. Kunjan" 4 => "K. Klaimukh" 5 => "T. Snabboon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.11604/pamj.2020.36.8.22923" "Revista" => array:5 [ "tituloSerie" => "Pan Afr Med J" "fecha" => "2020" "volumen" => "36" "paginaInicial" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32550971" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0245" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyperprolactinaemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "V.K.B. Prabhakar" 1 => "J.R.E. Davis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bpobgyn.2007.08.002" "Revista" => array:6 [ "tituloSerie" => "Best Pract Res Clin Obstet Gynaecol" "fecha" => "2008" "volumen" => "22" "paginaInicial" => "341" "paginaFinal" => "353" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17889620" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0250" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F.F. Casanueva" 1 => "M.E. Molitch" 2 => "J.A. Schlechte" 3 => "R. Abs" 4 => "V. Bonert" 5 => "M.D. Bronstein" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Endocrinol (Oxf)" "fecha" => "2006" "volumen" => "65" "paginaInicial" => "265" "paginaFinal" => "273" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0255" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guía clínica de diagnóstico y tratamiento del prolactinoma y la hiperprolactinemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "I. Halperin Rabinovich" 1 => "R. Cámara Gómez" 2 => "M. García Mouriz" 3 => "D. Ollero García-Agulló" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.endonu.2012.11.005" "Revista" => array:6 [ "tituloSerie" => "Endocrinol Nutr" "fecha" => "2013" "volumen" => "60" "paginaInicial" => "308" "paginaFinal" => "319" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23477758" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0260" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyperprolactinemia: a 12-year retrospective study at gynecologic endocrinology unit, Siriraj Hospital" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "R. Saejong" 1 => "C. Dangrat" 2 => "K. Techatrisak" 3 => "S. Angsuwatthana" 4 => "M. Rattanachaiyanont" 5 => "P. Tanmahasamut" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Med Assoc Thail Chotmaihet Thangphaet" "fecha" => "2013" "volumen" => "96" "paginaInicial" => "1247" "paginaFinal" => "1256" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0265" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Pituitary disease update [Internet]. Australian Journal of General Practice. Available from: <a target="_blank" href="https://www1.racgp.org.au/ajgp/2021/january-february/pituitary-disease-an-update">https://www1.racgp.org.au/ajgp/2021/january-february/pituitary-disease-an-update</a> [cited 14.5.21]." ] ] ] 26 => array:3 [ "identificador" => "bib0270" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical and etiological profile of hyperprolactinemia – data from a tertiary care centre" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.H. Zargar" 1 => "B.A. Laway" 2 => "S.R. Masoodi" 3 => "M.H. Bhat" 4 => "A.I. Wani" 5 => "M.I. Bashir" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Assoc Physicians India" "fecha" => "2005" "volumen" => "53" "paginaInicial" => "288" "paginaFinal" => "290" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15987012" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack636377" "titulo" => "Acknowledgements" "texto" => "<p id="par0170" class="elsevierStylePara elsevierViewall">We thank all the participants who have agreed to take part in this study. We wish to acknowledge the help of IRYCIS for the database and REDCap for data collection.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/25300164/0000006900000010/v1_202211180721/S2530016422001136/v1_202211180721/en/main.assets" "Apartado" => array:4 [ "identificador" => "63844" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originales" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25300164/0000006900000010/v1_202211180721/S2530016422001136/v1_202211180721/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422001136?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 3 | 2 | 5 |
2024 October | 58 | 28 | 86 |
2024 September | 58 | 34 | 92 |
2024 August | 59 | 31 | 90 |
2024 July | 43 | 23 | 66 |
2024 June | 43 | 22 | 65 |
2024 May | 37 | 30 | 67 |
2024 April | 51 | 19 | 70 |
2024 March | 41 | 21 | 62 |
2024 February | 37 | 12 | 49 |
2024 January | 52 | 6 | 58 |
2023 December | 53 | 17 | 70 |
2023 November | 64 | 8 | 72 |
2023 October | 99 | 7 | 106 |
2023 September | 43 | 5 | 48 |
2023 August | 51 | 2 | 53 |
2023 July | 59 | 8 | 67 |
2023 June | 45 | 12 | 57 |
2023 May | 11 | 7 | 18 |
2023 April | 8 | 1 | 9 |
2023 March | 5 | 5 | 10 |
2023 February | 4 | 4 | 8 |
2023 January | 9 | 9 | 18 |
2022 December | 20 | 16 | 36 |
2022 November | 23 | 17 | 40 |
2022 October | 0 | 9 | 9 |
2022 September | 0 | 5 | 5 |